pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›survodutide
drug · protein
save

survodutide

Phase 3updated 6mo ago
by Boehringer Ingelheim International GmbH🔗 ChEMBL
Phase 3
community read0 votes

Protein drug with a maximum clinical stage of Phase 3 (across all indications), with 5 investigational indications.

targets

Glucagon-like peptide 1 receptorGlucagon receptor

all catalysts(0)

nothing on the calendar yet

Trials studying survodutide

  • phase3ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Diseasenot yet recruitingn=600
  • phase3SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weightnot yet recruitingn=350
  • phase3LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosisrecruitingn=1,590
  • phase3A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)completedn=5,531
  • phase3A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugarrecruitingn=600
  • phase1A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injectorcompletedn=56
  • phase3LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosisrecruitingn=1,800
  • phase3A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Diseasecompletedn=274

News(10)

  • Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
    Novartis confirms that nine patients treated with its spinal muscular atrophy gene therapy Zolgensma have developed tumors; the FDA orders GLP-1 drugmakers to add a warning to their labels about th…
    biospace · 6d ago
  • Boehringer, Zealand’s obesity drug doesn’t elevate heart risk in key late-stage test
    The Phase 3 results help clarify the safety profile of Zealand and Boehringer Ingelheim’s survodutide, but analysts do not think the drug will find utility beyond patients with liver-related risk f…
    biospace · 8d ago
  • #AHA26: Boehringer to seek approval of obesity shot, but gaining market share could be tricky
    Boehringer Ingelheim will seek approval for its incretin shot survodutide for obesity next year, after a trial showed that the drug doesn’t increase patients’ risk of cardiovascular events like hea…
    endpoints · 8d ago
  • AHA: Boehringer aims for 2027 survodutide submission after obesity drug passes cardio test
    Boehringer Ingelheim is gearing up to take survodutide to regulators next year after the obesity drug proved its cardiovascular credentials in its latest phase 3 study.
    fiercebiotech · 12d ago
  • Zealand pens up to $1.2B deal with Generate for AI-designed obesity, metabolic drugs
    Obesity-focused Zealand Pharma is buying into Generate:Biomedicines’s generative AI platform to create new multispecific drug candidates.
    biospace · 1mo ago
  • Despite Zealand asset’s ‘intriguing’ weight loss, analysts underwhelmed by blood sugar numbers
    For the second time in a week, Zealand Pharma’s weight loss pipeline has delivered mixed results, this time in a Phase 2 trial for the Roche-partnered asset petrelintide.
    biospace · 1mo ago
  • 3 takeaways from a European obesity scientific meeting
    Eli Lilly impressed with its amylin-Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral and AbbVie and Boehringer gave glimpses into their conte…
    biopharma_dive · 1mo ago
  • Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again
    Despite meeting the primary endpoints in a Phase 3 trial, shares of Zealand Pharma dropped in premarket trading Thursday as the up to 9.8% weight loss reflected inferior loss to that generated by c…
    biospace · 1mo ago
  • Zealand's stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3
    A phase 3 trial of Boehringer Ingelheim’s survodutide in people with obesity and Type 2 diabetes has met its co-primary endpoints. Yet, with the readout echoing earlier data that underwhelmed analy…
    fiercebiotech · 1mo ago
  • Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decision
    As the FDA mulls whether to approve Takeda and Protagonist Therapeutics’ rusfertide, Zealand Pharma has sold its own rights to the blood cancer drug in return for $100 million.
    fiercebiotech · 3mo ago
view all news mentions →
generic
survodutide
MOA
Glucagon-like peptide 1 receptor agonist; Glucagon receptor agonist
indication
Liver Fibrosis
phase
phase_3
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?